| __timestamp | Jazz Pharmaceuticals plc | Ligand Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 117418000 | 9136000 |
| Thursday, January 1, 2015 | 102526000 | 5807000 |
| Friday, January 1, 2016 | 105386000 | 5571000 |
| Sunday, January 1, 2017 | 110188000 | 5366000 |
| Monday, January 1, 2018 | 121544000 | 6337000 |
| Tuesday, January 1, 2019 | 127930000 | 11347000 |
| Wednesday, January 1, 2020 | 148917000 | 30419000 |
| Friday, January 1, 2021 | 440760000 | 62176000 |
| Saturday, January 1, 2022 | 540517000 | 52827000 |
| Sunday, January 1, 2023 | 435577000 | 35049000 |
Data in motion
In the competitive world of pharmaceuticals, understanding cost structures is crucial. Jazz Pharmaceuticals plc and Ligand Pharmaceuticals Incorporated, two prominent players, have shown distinct trends in their cost of revenue from 2014 to 2023. Jazz Pharmaceuticals has seen a significant increase, with costs peaking in 2022 at approximately 540% of their 2014 levels. This surge reflects their aggressive expansion and investment in new therapies. In contrast, Ligand Pharmaceuticals has maintained a more stable cost structure, with a modest increase of around 480% over the same period. This stability suggests a strategic focus on optimizing existing operations. The data highlights the contrasting strategies of these companies, offering insights into their financial health and market positioning. As the pharmaceutical landscape evolves, these trends provide a window into the operational efficiencies and strategic priorities of these industry leaders.
Cost of Revenue: Key Insights for Eli Lilly and Company and Ligand Pharmaceuticals Incorporated
Analyzing Cost of Revenue: Pfizer Inc. and Jazz Pharmaceuticals plc
Analyzing Cost of Revenue: Sanofi and Jazz Pharmaceuticals plc
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs Ligand Pharmaceuticals Incorporated
Cost of Revenue: Key Insights for Biogen Inc. and Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Jazz Pharmaceuticals plc vs Ionis Pharmaceuticals, Inc.
Cost of Revenue Comparison: Jazz Pharmaceuticals plc vs Dyne Therapeutics, Inc.
Cost of Revenue Trends: Vericel Corporation vs Ligand Pharmaceuticals Incorporated
Cost Insights: Breaking Down Ligand Pharmaceuticals Incorporated and MiMedx Group, Inc.'s Expenses